Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Medroxyprogesterone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    88 result(s) found for: Medroxyprogesterone. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2017-002341-30 Sponsor Protocol Number: 1705-VLC-030-JG Start Date*: 2017-09-11
    Sponsor Name:INSTITUTO VALENCIANO DE INFERTILIDAD (IVI)
    Full Title: Usefulness of medroxyprogesterone acetate in the follicular phase for ovarian donors to prevent premature luteinization
    Medical condition: prevent premature luteinitation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10041244 - Social circumstances 10072070 Oocyte donor PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004328-73 Sponsor Protocol Number: BRAKE Start Date*: 2016-05-24
    Sponsor Name:Fundació Privada EUGIn
    Full Title: Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors
    Medical condition: Infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001984-21 Sponsor Protocol Number: 3/013/13 Start Date*: 2013-09-11
    Sponsor Name:University of Aberdeen & NHS Grampian
    Full Title: PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Protestogen Therapy
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-003203-32 Sponsor Protocol Number: 3115A1-3307-WW Start Date*: 2009-04-17
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-AND ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY OF THE EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS COMBINATIONS ON ENDOMETRIAL HYPERPLASIA AND PREVENTION OF OST...
    Medical condition: Menopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027309 Menopause and related conditions HLGT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-007653-12 Sponsor Protocol Number: AC-SWE-001 Start Date*: 2009-07-15
    Sponsor Name:Actelion Pharmaceuticals Sverige AB
    Full Title: Determination of ( 11 C) miglustat uptake in bone tissue and brain using Positron Emission Tomography (PET).
    Medical condition: Gaucher`s diseases type 1 and bone manifestations (patients)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002678-10 Sponsor Protocol Number: GF22002 Start Date*: 2023-03-07
    Sponsor Name:Ginefiv
    Full Title: Protocol with progestin-primed ovarian stimulation (PPOS) starting on day 5 versus protocol with progestin-primed ovarian stimulation (PPOS) in a conventional regimen from the start of the ovaria...
    Medical condition: Number of MII oocytes obtained in both groups
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004511-30 Sponsor Protocol Number: POF01 Start Date*: 2013-01-16
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: A randomised controlled trial to compare the effect of micronized progesterone and Medroxyprogesterone Acetate on the vascular elasticity, lipid profile and coagulation cascade of women with premat...
    Medical condition: Premature ovarian failure.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10036602 Premature ovarian failure LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001016-51 Sponsor Protocol Number: 05-UTROGEL-01 Start Date*: 2006-02-28
    Sponsor Name:Karolinska Hospital
    Full Title: In vivo effects of transdermal Estradiol+ oral Progesterone vs oral Conjugated Equine Estrogens + MedroxyProgesteroneAcetate on normal human breast cells proliferation: a randomized comparative study
    Medical condition: Menopausal symptoms
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001955-35 Sponsor Protocol Number: RG_11-054 Start Date*: 2012-02-15
    Sponsor Name:University of Birmingham
    Full Title: Single Arm Phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers
    Medical condition: Acute Myeloid Leukaemia (AML), Chronic Lymphocytic Leukaemia (CLL) and B-cell Non-Hodgkins Lymphoma (BNHL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001524-37 Sponsor Protocol Number: F1J MC HMEF Start Date*: 2005-06-29
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome
    Medical condition: Fibromyalgia syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10016631 Fibromyalgia syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004188-50 Sponsor Protocol Number: F1J-MC-HMEM Start Date*: 2006-02-10
    Sponsor Name:Eli Lilly and Company
    Full Title: Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain
    Medical condition: Diabetic Peripheral Neuropathic Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001295-36 Sponsor Protocol Number: SRM105106 Start Date*: 2007-08-22
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 ad...
    Medical condition: Treatment of moderate to extremely severe vasomotor symptoms in healthy postmenopausal women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003367-19 Sponsor Protocol Number: NUC-5/PSC Start Date*: 2017-09-28
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
    Medical condition: Primary Sclerosing Cholangitis (PSC) is a slowly progressing chronic cholestatic liver disease of assumed autoimmune, but finally unidentified etiology, characterized by a chronic inflammatory and ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) LT (Completed) FI (Trial now transitioned) CZ (Prematurely Ended) BE (Completed) DK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) SE (Completed) NO (Trial now transitioned) PL (Trial now transitioned) IE (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022313-25 Sponsor Protocol Number: CL-503012 Start Date*: 2011-01-17
    Sponsor Name:A.T. Development Switzerland SARL
    Full Title: International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA™ in Preventing Renal Function Decline in Patients With AA Amyloidosis
    Medical condition: Renal Function Decline in Patients With AA Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10002024 Amyloidosis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SE (Completed) GB (Completed) NL (Completed) CZ (Completed) FI (Completed) DE (Completed) ES (Completed) BE (Completed) PL (Completed) IT (Completed) BG (Completed) PT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002381-36 Sponsor Protocol Number: A6061046 Start Date*: 2008-01-31
    Sponsor Name:Pfizer Inc.
    Full Title: A MULTI-CENTER, LONG TERM, OPEN-LABEL STUDY OF [S,S]-REBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY IN PATIENTS WITH FIBROMYALGIA
    Medical condition: pain and associated symptoms in patients with fibromyalgia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048439 Fibromyalgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Prematurely Ended) NL (Prematurely Ended) GB (Completed) DE (Prematurely Ended) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004150-16 Sponsor Protocol Number: CL-503015 Start Date*: 2014-06-19
    Sponsor Name:A.T. Development Switzerland SARL
    Full Title: International Open-Label Extension of the Phase 3 Study CL-503012 with KIACTA™ in Patients with AA Amyloidosis
    Medical condition: AA Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003484-31 Sponsor Protocol Number: F1J-MC-HMEN Start Date*: 2006-12-13
    Sponsor Name:Eli Lilly and Company Ltd.
    Full Title: Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain
    Medical condition: Chronic Low Back Pain
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003988 Back pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002219-26 Sponsor Protocol Number: RA1100849 Start Date*: 2005-09-08
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react...
    Medical condition: Rheumatoid arthritis (RA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) DE (Completed) DK (Prematurely Ended) ES (Completed) GB (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001072-21 Sponsor Protocol Number: MKN106762 Start Date*: 2006-08-08
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A double-blind placebo-controlled study of the efficacy and safety of the P38 Map Kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma
    Medical condition: Neuropathic pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000544-86 Sponsor Protocol Number: 11848 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG; D-51368 Leverkusen
    Full Title: A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or me...
    Medical condition: unresectable and/or metastatic renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 08:31:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA